|1.||Clarke, Lane L: 1 article (04/2006)|
|2.||Boyle, Kathryn T: 1 article (04/2006)|
|3.||Levitt, Roy C: 1 article (04/2006)|
|4.||Walker, Nancy M: 1 article (04/2006)|
|5.||Simpson, Janet E: 1 article (04/2006)|
|6.||Knight, Darryl: 1 article (05/2004)|
|1.||Cystic Fibrosis (Mucoviscidosis)
05/01/2004 - "Phase I trials with talniflumate had been completed by August 2001, and phase II trials were underway in Ireland for the treatment of cystic fibrosis."
04/01/2006 - "Talniflumate increases survival in a cystic fibrosis mouse model of distal intestinal obstructive syndrome."
05/01/2004 - "Talniflumate, an anti-inflammatory molecule that was originally developed by Laboratorios Bago, is currently being developed by Genaera as a mucoregulator for the treatment of cystic fibrosis, chronic obstructive pulmonary disease and asthma. "
|2.||Chronic Obstructive Pulmonary Disease (COPD)
|3.||Intestinal Diseases (Diseases, Intestinal)
04/01/2006 - "We investigated the effects of talniflumate (Lomucin, Genaera Corporation, Plymouth Meeting, PA), a compound that may be beneficial to treatment of CF intestinal disease based on three mechanisms of action: mucus synthesis inhibition by blockade of the murine calcium-activated chloride channel 3 (mCLCA3), nonsteroidal anti-inflammatory effects, and inhibition of Cl(-)/HCO (-)(3) exchanger(s) involved in intestinal NaCl absorption. "
|4.||Asthma (Bronchial Asthma)